



# Sector Close Up: Pharmaceutical and Biotech Stocks – Is Gene Therapy the Next Major Breakthrough in Cancer Treatment?

ECON Corporate Services, October 22, 2007

URL: <http://www.pr9.net/business/financial/6608october.html>

*InvestorIdeas.com, a leading online global investor resource, issues the Sector Close Up – Pharmaceutical and Biotech Stocks. Gene therapy, which entails the introduction of genetic material into a person's cells to fight or prevent disease, is a highly promising area but one that is long on theory and short on commercial product.*

PR9.NET October 22, 2007 - POINT ROBERTS, Wash., Delta B.C., - InvestorIdeas.com, a leading online global investor resource, issues the Sector Close Up – Pharmaceutical and Biotech Stocks. Gene therapy, which entails the introduction of genetic material into a person's cells to fight or prevent disease, is a highly promising area but one that is long on theory and short on commercial product.

Benda Pharmaceutical, Inc. (OTCBB: BPMA) is a China-based pharmaceutical company that has become recognized for its cancer gene therapy treatment Gendicine®, which represents the world's first gene therapy medicine on the market for the treatment of cancer. Gendicine® has been used to treat more than 50 types of malignant tumors across 6,000 patients, including more than 1,800 foreigners. According to the Company, in clinical trials on 135 patients affected by head and neck tumors, 64% had their tumors eliminated after one month of Gendicine® treatment - a 340% increase in efficacy relative to traditional treatments.

According to Justin Davis from After Market Support, LLC, North American representatives for Benda Pharmaceutical, "The addition of Gendicine® to Benda's drug portfolio thrusts the Company to the leading edge of both the gene therapy revolution and the world's ongoing fight against cancer. As the first cancer-treating gene therapy drug available to the public – anywhere - Gendicine® has garnered international attention and has turned both the medical and investing spotlights directly on Benda. Moreover, the demonstrated efficacy of Gendicine® has already translated into immediate financial returns for Benda - \$3.8 MM in orders in one day after a recent medical conference in China. With the Company preparing to present the latest independent findings to an international gene therapy symposium in Europe, Benda finds itself at the cusp of what could become a global phenomenon."

Another player in the gene therapy arena is Introgen Therapeutics, Inc. (Chart), a biopharmaceutical company focused on targeted molecular therapies for the treatment of cancer and other diseases. Introgen's gene therapy drug ADVEXIN® has not yet been approved – it is currently in Phase 3 clinical trials for the treatment of head and neck cancer and Li-Fraumeni Syndrome. According to the Company, regulatory filings in both the United States and in Europe are expected to be completed by the end of 2007.

Showcase Pharmaceutical Company:

Benda Pharmaceutical Inc. (OTCBB: BPMA), a China-based pharmaceutical company, is a pure play on explosive Chinese pharmaceutical spending and the global search for a cancer cure. For more info visit: <http://www.investorideas.com/co/bpma/>  
Compensation is disclosed in disclaimer

About InvestorIdeas.com

InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing covering over thirty industry sectors and global markets including China, India, Middle East and Australia.

FULL ARTICLE: <http://www.investorideas.com/Companies/ViewDocument.asp?ID=5166>

InvestorIdeas.com Disclaimer: [www.investorideas.com/About/Disclaimer.asp](http://www.investorideas.com/About/Disclaimer.asp).

For more information contact:

Dawn Van Zant: 800-665-0411 - [dvanzant@investorideas.com](mailto:dvanzant@investorideas.com)

Source: InvestorIdeas.com, Benda Pharmaceutical, Inc.

###

## About ECON Corporate Services

InvestorIdeas.com® - [www.investorideas.com](http://www.investorideas.com) is a leading global investor and industry research resource portal specialized in sector investing news, stock directories and research links. The site covers over thirty industry sectors and global markets, featuring: investor newsletters, Blogs, RSS news feeds, investor conferences and forums, audio interviews and Podcasts and exclusive industry articles and financial columnists.

**Phone:** 800-665-0411  
**Website:** <http://www.investorideas.com>  
**E-Mail:** [dvanzant@investorideas.com](mailto:dvanzant@investorideas.com)

---

